Ronald Stewart, DO
Cardiovascular Disease · Sterling Heights, MINPI 1801889654
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.6% of the total across 137 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 17.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $621 and has fallen 58.1% since, to $260 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in MI, where the typical reported total is $2,775.
Across 137 payments — averaging $19.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$460
- Pfizer$413
- Merck$314
- Boehringer Ingelheim$291
- Baxter Healthcare$180
- AstraZeneca$173
- plus $782 from 19 others
What the payments were for
- Food & beverage$2,52597%
- Other$883%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 28 | $460 |
| Pfizer | 21 | $413 |
| Merck | 18 | $314 |
| Boehringer Ingelheim | 13 | $291 |
| Baxter Healthcare | 5 | $180 |
| AstraZeneca | 12 | $173 |
| Novo Nordisk | 5 | $110 |
| Kiniksa Pharmaceuticals, Ltd. | 4 | $109 |
| Novartis | 5 | $94 |
| Amarin Pharma, Inc. | 6 | $77 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $52 |
| Philips North America LLC | 3 | $45 |
| Actelion Pharmaceuticals US, Inc. | 1 | $39 |
| Edwards Lifesciences | 1 | $38 |
| Heartflow, Inc. | 2 | $34 |
| Medtronic | 1 | $25 |
| Kestra Medical Technology Services, Inc. | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $20 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $20 |
| Irhythm Technologies, Inc. | 1 | $19 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Bardy Diagnostics, Inc. | 1 | $11 |
How this compares
$2,613 in reported general payments places this provider in the 45th percentile of 760 cardiovascular disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 115 | $139,945 |
| TrulicityDulaglutide | 31 | $59,429 |
| JardianceEmpagliflozin | 47 | $59,001 |
| EntrestoSacubitril/Valsartan | 31 | $38,845 |
| FarxigaDapagliflozin Propanediol | 22 | $23,136 |
| Breo ElliptaFluticasone/Vilanterol | 35 | $18,010 |
| Repatha SyringeEvolocumab | 16 | $11,619 |
| Icosapent Ethyl | 20 | $4,850 |
| LipitorAtorvastatin Calcium | 12 | $3,559 |
| Enalapril Maleate | 76 | $3,312 |
| Losartan Potassium | 197 | $3,184 |
| Ranolazine ErRanolazine | 26 | $2,859 |
| Atorvastatin Calcium | 186 | $2,408 |
| Metoprolol Succinate | 123 | $2,254 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $2,134 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Lipitor | $413 | $143,504127 claims |
| Boehringer IngelheimJardiance | $291 | $59,00147 claims |
| NovartisEntresto | $94 | $38,84531 claims |
| AstraZenecaFarxiga | $173 | $23,13622 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 760 cardiovascular disease providers in Michigan.
Other cardiovascular disease in Sterling Heights
- Samer KazzihaSterling Heights$58K
- Marschall RungeAnn Arbor$1.8M
- Jihad MustaphaGrand Rapids$1.6M
- Vallerie McLaughlinAnn Arbor$947K
- Pedro Villablanca SpinettoDetroit$620K
- Stanley ChetcutiAnn Arbor$573K
- David HainesRoyal Oak$492K
- Steven AlmanyTroy$471K
- David StroblLansing$445K
- Herman KadoSouthfield$442K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.